Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Interventional × Macular Degeneration × Clear all

Phase

Status

Sponsor Class

OTHER 2 INDUSTRY 1

Study Type

Observational 2 Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2575 Carcinoma, Non-Small-Cell Lung 2146 Breast Neoplasms 1848 Neoplasm Metastasis 1093 Colorectal Neoplasms 1080 Prostatic Neoplasms 956 Melanoma 861 Multiple Myeloma 850 Ovarian Neoplasms 798 Recurrence 761 Leukemia, Myeloid, Acute 731 Pancreatic Neoplasms 666 Lung Neoplasms 665 Lymphoma, Non-Hodgkin 645 Lymphoma 595 Stomach Neoplasms 548 Carcinoma, Hepatocellular 504 Carcinoma, Renal Cell 487 Squamous Cell Carcinoma of Head and Neck 466 Leukemia, Lymphocytic, Chronic, B-Cell 440 Lymphoma, Follicular 413 Head and Neck Neoplasms 399 Glioblastoma 392 Advanced Solid Tumors 375 Small Cell Lung Carcinoma 357 Lymphoma, Large B-Cell, Diffuse 355 Triple Negative Breast Neoplasms 354 Leukemia 352 Uterine Cervical Neoplasms 320 Advanced Solid Tumor 317

Interventions

brolucizumab 1 aflibercept 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡